Loading...
Immunovant, Inc.
IMVT•NASDAQ
Healthcare
Biotechnology
$16.95
$-1.37(-7.48%)
Immunovant, Inc. (IMVT) Financial Performance & Income Statement Overview
Review Immunovant, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-42.44%
↓ 42.44%
Net Income Growth
-22.93%
↓ 22.93%
Operating Cash Flow Growth
-13.83%
↓ 13.83%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
-258650.00%
↓ 258650.00%
ROE
-80.60%
↓ 80.60%
ROIC
0.00%
Immunovant, Inc. (IMVT) Income Statement & Financial Overview
Review Immunovant, Inc.'s (IMVT) income statement with detailed quarterly and annual figures.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $1.50M |
| Cost of Revenue | $0.00 | $0.00 | $80000.00 | $64000.00 |
| Gross Profit | $0.00 | $0.00 | -$80000.00 | $1.44M |
| Gross Profit Ratio | $0.00 | $0.00 | $0.96 | |
| R&D Expenses | $94.52M | $97.27M | $75.47M | $66.06M |
| SG&A Expenses | $19.78M | $18.47M | $18.73M | $14.76M |
| Operating Expenses | $114.30M | $115.74M | $94.20M | $80.81M |
| Total Costs & Expenses | $114.30M | $115.74M | $94.28M | $80.88M |
| Interest Income | $4.59M | $6.07M | $7.18M | $8.38M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $99000.00 | $89000.00 | $80000.00 | $64000.00 |
| EBITDA | -$110.87M | -$115.65M | -$94.20M | -$80.81M |
| EBITDA Ratio | -$53.88 | |||
| Operating Income | -$114.30M | -$115.74M | -$94.28M | -$80.88M |
| Operating Income Ratio | -$53.92 | |||
| Other Income/Expenses (Net) | $3.33M | $6.70M | $7.21M | $5.79M |
| Income Before Tax | -$110.97M | -$109.04M | -$87.07M | -$75.09M |
| Income Before Tax Ratio | -$50.06 | |||
| Income Tax Expense | $152000.00 | $78000.00 | $77000.00 | $232000.00 |
| Net Income | -$111.12M | -$109.12M | -$87.15M | -$75.32M |
| Net Income Ratio | -$50.21 | |||
| EPS | -$0.76 | -$0.74 | -$0.60 | -$0.52 |
| Diluted EPS | -$0.76 | -$0.74 | -$0.60 | -$0.52 |
| Weighted Avg Shares Outstanding | $146.92M | $146.47M | $146.09M | $145.36M |
| Weighted Avg Shares Outstanding (Diluted) | $146.92M | $146.47M | $146.09M | $145.36M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan